Switching GLP-1 providers: what transfers, what is forfeited, and what starts over
Very little carries over. A compounded prescription is prepared for an identified patient by a named pharmacy, so it isn't a portable object the way a retail prescription is — the new seller writes a new one. What follows you is your history, your tolerance to the dose you reached, and whatever money you have already committed to the seller you are leaving.
What this comes down to
- A compounded drug is made for an identified individual patient on a prescription. Switching sellers generally means a new intake, a new prescriber and a new pharmacy rather than a transfer.
- Whether you can leave cheaply is decided before you join. 110 of the 190 sellers we have written up publish a month-to-month price for everything they sell; 41 publish one for nothing.
- Vial concentration is not standardized between compounders, so the same milligram dose can be a different number of units on the syringe at the new seller. The FDA has adverse event reports from that conversion going wrong.
- No randomized trial has studied switching between semaglutide and tirzepatide. The identical filter finds 23 trials that compare the two head to head.
Why this is not a pharmacy transfer
A 503A compounding pharmacy makes a drug for an identified individual patient on a prescription, and the FDA's own framing is that compounded drugs should only be used where an approved drug cannot meet the medical need[1]. That's a different object from a retail prescription for an approved product, which any licensed pharmacy can fill. The practical consequence is that the new company runs its own intake, its own clinician review and its own pharmacy relationship.
So the list of what actually moves with you is short, and worth being honest about.
| Does it carry over? | |
|---|---|
| Your medical history and current dose | Yes, if you report it — you are the record |
| The prescription itself | Generally no, for a compounded product |
| The pharmacy that made your vial | No, unless the new seller uses the same one, which it rarely names |
| Vial concentration and your units-per-dose | No, and this is the one that causes harm |
| Money already paid or committed | No |
| Labs already drawn | Sometimes, if you can obtain and send them |
What follows you from one telehealth seller to the next.
The handover that has produced actual harm reports
A compounded vial is drawn with an insulin syringe marked in units while the prescription is written in milligrams, and the conversion depends on that vial's concentration. Concentration isn't standardized between compounders. Arriving at a new seller on the dose you had reached means recalculating that conversion against a vial you have never used.
The FDA has received multiple adverse event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide — from patients measuring and self-administering incorrect doses, and in some cases from clinicians miscalculating them[2]. A switch is precisely the moment those two conditions coincide.
The concentration of the new vial, in milligrams per milliliter, and how many units on the syringe that makes your prescribed dose. Ask the new seller for both numbers rather than assuming your old count transfers. Nobody here holds a medical license, and that is a question for the prescriber writing the new prescription.
Switching the molecule, not only the seller
Plenty of switches are really a change of molecule — semaglutide to tirzepatide, usually. The two have been compared head to head in trials. The transition between them has not been studied as its own question.
PubMed, via the E-utilities API
switch*[tiab] AND semaglutide[tiab] AND tirzepatide[tiab] AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 0. Positive control — semaglutide and tirzepatide together, identical trial filter — returned 23 through the identical filter in the same session.
The control removes only the switching term and keeps everything else identical: 23 randomized trials study these two drugs together. Add the switching term and the count is zero. Unfiltered, switching alongside both molecules returns 21 records, which are observational reports and reviews rather than trials.
That's not an argument against switching. It's a statement about what evidence exists to plan one with — which is the same answer the microdosing question gets, and for the same reason: the market moved faster than anybody measured it.
The part that is decided before you ever want to leave
Whether switching is cheap or expensive is a property of the contract you signed, not of the switch. 110 of the 190 sellers we have written up publish a month-to-month price for everything they sell, 41 publish one for nothing, and 39 publish one for some drugs and not others[5]. A seller in the second group has, in practice, priced leaving.
And the terms decide the rest. One seller's membership terms commit you to a three-month initial term billed in installments and state there is no refund once a term has been paid and no waiver of the unpaid installments[3]. Another states plainly that membership and medication order fees are non-refundable once paid[4]. Seven of these documents, read in full is where the rest of that reading lives.
The common expensive mistake is signing up with the new seller before canceling the old one, on the theory that you will sort the overlap out later. Where the old plan renews on a fixed cycle, that overlap is a whole cycle. Check the renewal date first and start the new intake after it, not before.
The order to do it in
- Find the renewal date and the cancellation method in the seller's own terms, not in the app. The billing cycles are not always what they are called.
- Write down your current molecule, dose in milligrams, and how long you have been on it.
- Ask the new seller, before paying, what a single month costs at your dose and what the vial concentration is.
- Cancel the old plan effective at the end of the period you have already paid for, then start the new intake.
- Compare the two on total cost rather than on headline: the calculator puts the medication and any recurring fee over the months you expect to continue.
One more thing worth checking on the way in. The FDA's telehealth red-flag list includes a company that sends medicine that looks different from what you received before, and a company with no licensed doctor available to answer questions after the medicine arrives[2]. The first of those is a normal experience when you switch compounders, and the second is what makes it either fine or frightening. How a telehealth prescription actually happens walks the whole list.
Questions people actually ask
Can I transfer my compounded semaglutide prescription to another company?
Generally no. A compounded drug is prepared for an identified individual patient by a particular pharmacy on a particular prescription, so the new seller runs its own intake and its own clinician review and issues a new prescription through its own pharmacy.
Will I have to start at the lowest dose again if I switch?
That is a decision for the prescriber at the new seller, based on the history you report and how long you have been at your current dose. Nobody here holds a medical license. What you can do is arrive with the molecule, the milligram dose and the duration written down.
Is it safe to switch compounding pharmacies mid-course?
The specific risk is the dose conversion. Vial concentration is not standardized between compounders, so the same milligram dose can be a different number of units on the syringe, and the FDA has adverse event reports, some requiring hospitalization, tied to that calculation going wrong.
Do I lose money already paid when I leave a telehealth plan?
Usually yes, and often more than the current month. One seller's published terms commit you to a three-month initial term and state there is no refund once a term has been paid and no waiver of the unpaid installments. Check the renewal date before you start anywhere new.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025A 503A pharmacy compounds a drug for an identified individual patient on a prescription; compounded drugs are not FDA approved; and consumers buying through telehealth platforms may not know the identity of the compounder that produced their drug.
- 2.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026Multiple adverse event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide from patients or clinicians miscalculating doses; and the telehealth red flags covering medicine that looks different from what you received before and a company with no licensed doctor available after the medicine arrives.
- 3.Membership Terms and Conditions. Calibrate Health, 2025. Source · Document dated October 2025An initial term of three months billed in installments, and the statement that the company does not provide refunds once a term has been paid or a waiver of any unpaid installments of fees during the initial term.
- 4.Terms of Service. Lemonaid Health, 2026. Source · Document dated May 2026Membership fees charged in advance of the period they cover, the statement that membership and medication order fees are non-refundable once paid, and extended commitment options renewing every 80, 160 or 332 days with payment due in full and in advance.
- 5.The Telehealth Graded price record. Telehealth Graded, 2026. SourceThe counts of sellers publishing a month-to-month price, publishing none, and publishing one for some drugs and not others are computed at build time from the site's own review records.
Key figures